Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 ...

"We are looking forward to exploring the potential of the PRMT5 inhibitor, which could improve outcomes for patients with MTAP-deleted tumors who often have a poor prognosis," said Juergen ...